Insulin Glargine U100 Utilization in Patients with Type 2 Diabetes in an Italian Real-World Setting: A Retrospective Study
Table 3
Correlation between daily insulin dose (IU, median) and HbA1c levels stratified according to the therapeutic regimen.
HbA1c
Insulin glargine only ()
Insulin glargine plus other oral glucose-lowering drugs ()
Insulin glargine plus DPP-4 inhibitors ()
Insulin glargine plus rapid-acting insulin ()
Patients with HbA1c value (%)
Daily dose (IU)
Patients with HbA1c value (%)
Daily dose (IU)
Patients with HbA1c value (%)
Daily dose (IU)
Patients with HbA1c value (%)
Daily dose (IU)
Mean (SD)
Median (IQR)
Mean (SD)
Median (IQR)
Mean (SD)
Median (IQR)
Mean (SD)
Median (IQR)
<7%
53.8
42.4 (35.1)
35.7 (37.5)
29.3%
34.1 (40.1)
20.9 (38.5)
34.1%
39.9 (32.4)
43.0 (37.2)
28.8^
40.4 (34.2)
20.9 (35.8)°
7-8%
19.6
32.6 (33.9)
15.3 (42.7)
35.2%
30.3 (39.3)
16.6 (29.2)
34.5%
34.0 (33.6)
19.7 (39.8)
35.1^
30.3 (46.7)
19.9 (24.5)
8-9%
13.9
34.6 (34.3)
18.7 (38.4)
19.1%
26.5 (32.7)
16.7 (22.2)
21.7%
30.6 (28.3)
17.1 (38.9)
22.2^
30.0 (34.4)
20.4 (23.8)
>9%
12.7
35.6 (27.7)
28.5 (36.9)
16.4%
30.7 (34.4)
18.2 (32.5)
9.6%
28.0 (26.0)
19.2 (27.8)
14.0^
29.5 (23.0)
22.7 (24.3)
The analysis was carried out on the cohort of patients for which the laboratory data were available and with at least 3 months of follow-up. ^ among groups. ° among groups.
